Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Enrollment
- 3000
- Locations
- 1
- Primary Endpoint
- Long term cardiovascular mortality
- Last Updated
- 12 years ago
Overview
Brief Summary
The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.
Detailed Description
Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected. The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients presenting with shortness of breath secondary or not to heart failure, even with cardiac shock and LVAD.
- •Patients with valvular disease
- •chronic stable heart failure.
- •post- partum Cardiomyopathy
Exclusion Criteria
- •terminal cancer
- •progressive neurological disease
- •pregnancy
- •opposition of the patient
Outcomes
Primary Outcomes
Long term cardiovascular mortality
Time Frame: Prospective at 12 months
To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months.
Secondary Outcomes
- Diagnostic value of new biomarkers.(at day 0)
- Cardiac hospitalization(s) at 3, 6,12 and 24 months(Prospective at 12 months)